Transcode Therapeutics, Inc.
RNAZ Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.67
KIRA · Stoqly’s AI analyst, in plain words
- Transcode Therapeutics, Inc. lost $34.7M in fiscal 2025.
- Free cash flow was −$19.5M in fiscal 2025, — of revenue.
Market cap
$1.6M
P/E
—
Revenue
—
Net income
−$34.7M
Free cash flow
−$19.5M
Operating margin
—
Transcode Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$34.7M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Transcode Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- Transcode Therapeutics, Inc.
- CIK
- 0001829635
Transcode Therapeutics, Inc. · RNAZ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$6.8M | −$17.6M | −$18.5M | −$16.8M | −$34.7M |
| Diluted EPS | −$0.81 | −$1,082.79 | −$3,419.01 | −$1,336.63 | −$52.59 |
| Cash | |||||
| Cash from operations | −$5.3M | −$15.8M | −$18.1M | −$13.3M | −$19.5M |
| Capital expenditure | $0.3M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$5.5M | −$15.9M | −$18.1M | −$13.4M | −$19.5M |
| Share count change | 81.7% | −99.8% | −66.7% | 133.3% | 5,373.8% |
| Debt and strength | |||||
| Cash and short-term investments | $20.8M | $5.0M | $2.8M | $5.8M | $17.8M |
| Shareholders' equity | $20.4M | $3.2M | $1.6M | −$2.0M | $10.3M |
| Current ratio | 9.0x | 1.7x | 1.3x | 2.6x | 6.3x |
| Interest coverage | −64.7x | −582.3x | −347.4x | −584.4x | −4,239.4x |
| Returns and quality | |||||
| Return on equity | −80.5% | −148.6% | −759.9% | — | −833.5% |
| Return on tangible equity | −33.5% | −542.0% | −1,130.3% | — | — |
| Altman Z'' | 11.0 | −25.1 | −52.8 | −39.0 | −1.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Transcode Therapeutics, Inc. · RNAZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.67 a share, the company is worth $1.6M.
Source: SEC EDGAR XBRL filings (CIK 0001829635). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.